

RESOURCES

Publications

1. Aoki FY, Tyring S, Diaz-Mitoma F, Gross G, Gao J, Hamed K. Single-day patient initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial. *Clin Infect Dis* 2006;42:8–13.
2. Arvin AM, Prover CG: Herpes simplex virus type 2 – a persistent problem. *New Engl J Med* 1997; 337:1158-1159.
3. Benedetti JK, Corey L, Ashley R. Recurrence rates in genital herpes after symptomatic first-episode infection. *Ann Intern Med* 1994;121:847–54.
4. Bergstrom T, Vahline A, Alestig K, et al. Primary and recurrent herpes simplex virus type 2-induced meningitis. *J Infect Dis* 1990; 162:322-330.
5. Bodsworth NJ, Crooks RJ, Borelli S, et al. Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial. *Genitourinary Med* 1997;73:110–6.
6. Brock BV, Selke S, Benedetti J, et al. Frequency of asymptomatic shedding of herpes simplex virus in women with genital herpes. *JAMA* 1990; 263:418-420.
7. Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines, 2006. *MMWR* 2006;55(RR-11):16-20. Available from URL: <http://www.cdc.gov/STD/treatment/>
8. Chosidow O, Drouault Y, Leconte-Veyriac F, et al. Famciclovir vs. aciclovir in immunocompetent patients with recurrent genital herpes infections: a parallel-groups, randomized, double-blind clinical trial. *British J Dermatol* 2001;144:818–24.
9. Conant MA, Schacker TW, Murphy RL, et al. Valaciclovir versus aciclovir for herpes simplex virus infection in HIV-infected individuals: two randomized trials. *Int J STD AIDS* 2002;13:12–21.
10. Corey L, Adams HG, Brown ZA, et al. Genital herpes simplex virus infections: clinical manifestations, course, and complications. *Ann Intern Med* 1983; 98:958-972.
11. Corey L, Spear PG. Infections with herpes simplex viruses. *New Engl J Med* 1986; 314:686-691 and 749-756.
12. Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. *N Engl J Med* 2004;350:11–20.
13. Corey L. Herpes Simplex Virus Type 2 and HIV-1: The Dialogue between the 2 organisms continues. *JID* 2007;195:1242-4.
14. DeJesus E, Wald A, Warren T, et al. Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects. *J Infect Dis* 2003;188:1009–16.
15. Diaz-Mitoma F, Sibbald RG, Shafran SD, Saltzman RL. Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial. *JAMA* 1998;280:887–92.
16. Engelberg R, Carrell D, Krantz E, Corey L, Wald A. Natural history of genital herpes simplex virus type 1 infection. *Sex Transmit Dis* 2003;30:174–7.

17. Faro S. A review of famciclovir in the management of genital herpes. *Infect Dis Obstet Gynecol* 1998; 6(1): 38-43.
18. Fife KH, Barbarash RA, Rudolph T et al. Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection. Results of an international, multicenter, double-blind, randomized clinical trial. The Valaciclovir International Herpes Simplex Virus Study Group. *Sex Transm Dis* 1997 Sep; 24(8): 481-6.
19. Fleming DT, McQuillan GM, Johnson RE et al: Herpes simplex virus type 2 in the United States, 1976 to 1995. *N Engl J Med* 1997; 337; 1105-11.
20. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 increases HIV acquisition in men and women: A systematic review and meta-analysis of longitudinal studies. *AIDS* 2006; 20:73-83.
21. Henry RE, Wegmann JA, Hartle JE, Christopher GW. Successful oral acyclovir desensitization. *Ann Allergy* 1993;70:386-8.
22. Holmes KK, Sparling PF, Mardh P-A, Lemon SM, Stamm WE, Piot P, Wasserheit JN (editors). *Sexually transmitted diseases*, 3rd ed. New York (NY): McGraw-Hill, 1999.
23. Koelle DM, Benedetti J, Langenberg A, Corey L. Asymptomatic reactivation of herpes simplex virus in women after the first episode of genital herpes. *Ann Int Med* 1992; 116:443-437.
24. Langenberg AGM, Corey L, Ashley RL et al. A prospective study of new infections with herpes simplex virus type 1 and type 2. *N Engl J Med* 1999; 341: 1432-8.
25. Leone PA, Trottier S, Miller JM. Valacyclovir for episodic treatment of genital herpes: a shorter 3-day treatment course compared with 5-day treatment. *Clin Infect Dis* 2002;34:958–62.
26. Mertz GJ, Benedetti J, Ashley R, Selke S, Corey L. Risk factors for the sexual transmission of genital herpes. *Ann Int Med* 1992; 116:197-202.
27. Mertz GJ, Schmidt O, Jourden JL, et al. Frequency of acquisition of first-episode genital infection with herpes simplex virus from symptomatic and asymptomatic source contacts. *Sex Trans Dis* 1985; 12:33-39.
28. Mertz GJ, Loveless MO, Levin MJ, et al. Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women. A multicenter, double-blind, placebo-controlled trial: Collaborative Famciclovir Genital Herpes Research Group. *Arch Intern Med* 1997;157:343–9.
29. Miyai T, Turner KR, Kent CK, et al. The psychosocial impact of testing individuals with no history of genital herpes for herpes simplex virus type 2. *Sex Transm Dis* 2004;31:517–21.
30. Nagot N, Ouédraogo A, Foulongne V, et al. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. *N Engl J Med* 2007;356(8):790-9.
31. Patel R, Bodsworth NJ, Woolley P, et al. Valaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. *Genitourinary Med* 1997;73:105–9.
32. Patel, R. Antiviral agents for the prevention of the sexual transmission of herpes simplex in discordant couples. *Curr Opin Infect Dis* 2004; 17:45-48.

33. Posavad CM, Wald A, Kuntz S, et al. Frequent reactivation of herpes simplex virus among HIV-1–infected patients treated with highly active antiretroviral therapy. *J Infect Dis* 2004;190:693–6.
34. Reitano M, Tyring S, Lang W, et al. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: A large-scale dose range-finding study. *J Infect Dis* 1998; 178: 603-610.
35. Reyes M, Shaik NS, Graber JM, et al. Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics. *Arch Intern Med* 2003;163:76–80.
36. Roberts CM, Pfister JR, Spear SJ. Increasing proportion of herpes simplex virus type 1 as a cause of genital herpes infection in college students. *Sex Transm Dis* 2003;30:801–2.
37. Romanowski B, Aoki FY, Martel AY, et al. Efficacy and safety of famciclovir for treating mucocutaneous herpes simplex infection in HIV-infected individuals. *AIDS* 2000;14:1211–7.
38. Romanowski B, Valtrex HS230017 Study Group, Marina RB, Roberts JN. Patients' preference of valacyclovir once-daily suppressive therapy versus twice-daily episodic therapy for recurrent genital herpes: a randomized study. *Sex Transm Dis* 2003;30:226–31.
39. Safrin S, Assaykeen T, Follansbee S, et al. Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: preliminary data. *J Infect Dis* 1990; 161:1078-1084.
40. Safrin S. Treatment of acyclovir-resistant herpes simplex virus infections in patients with AIDS. *J AIDS* 1992; 5(Suppl.1):S29-S32.
41. Scott LL, Hollier LM, McIntire D, Sanchez PJ, Jackson GL, Wendel GD Jr Acyclovir suppression to prevent recurrent genital herpes at delivery. *Infect Dis Obstet Gynecol* 2002;10:71–7.
42. Scoular A, Gillespie G, Carman WF. Polymerase chain reaction for diagnosis of genital herpes in a genitourinary medicine clinic. *Sex Transm Infect* 2002;78:21–5.
43. Scoular A. Using the evidence base on genital herpes: optimising the use of diagnostic tests and information provision. *Sex Transm Infect* 2002;78:160–5.
44. Sheffield JS, Hollier LM, Hill JB, Stuart GS, Wendel GD Jr Acyclovir prophylaxis to prevent herpes simplex virus recurrence at delivery: a systematic review. *Obstet Gynecol* 2003;102:1396–403.
45. Sizemore JM, Lkeman F, Whitley R, Hughes A, Hook EW. The spectrum of genital herpes simplex virus infection in men attending a sexually transmitted diseases clinic. *JID* 2006;193:905-11.
46. Song B, Dwyer DE, Mindel A. HSV type specific serology in sexual health clinics: use, benefits, and who gets tested. *Sex Transm Infect* 2004;80:113–7.
47. Stone KM, Reiff-Eldridge R, White AD, et al. Pregnancy outcomes following systemic prenatal acyclovir exposure: conclusions from the International Acyclovir Pregnancy Registry, 1984–1999. *Birth Defects Research (Part A)* 2004;70:201–7.
48. Strick LB, Wald A, Celum C. Management of herpes simplex virus type 2 infection in HIV Type 1-infected persons. *CID* 2006;43:347-56.

49. Wald A, Zeh J, Barnum G, et al: Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. *Ann Intern Med* 1996; 124:8-15.
50. Wald A. New therapies and prevention strategies for genital herpes. *Clin Infect Dis* 1999; 28: Suppl 1:S4-13.
51. Wald A, Langenberg AG, Link K, et al.. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. *JAMA* 2001;27;285:3100-6.
52. Wald A, Carrell D, Remington M, Kexel E, Zeh J, Corey L. Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection. *Clin Infect Dis* 2002;34:944–8.
53. Wald A, Huang M-L, Carrell D, Selke S, Corey L. Polymerase chain reaction for detection of herpes simplex virus (HSV) DNA on mucosal services: comparison with HSV isolation in cell culture. *J Infect Dis* 2003;188:1345–51.
54. Wald A, Langerberg AGM, Krantz E, et al. The relationship between condom use and herpes simplex virus acquisition. *Ann Intern Med* 2005;143:707–13.
55. Wald A, Krantz E, Selke S, Lairson E, Morrow RA, Zeh J. Knowledge of partners genital herpes protects against herpes simplex virus typrpe 2 acquisition. *JID* 2006;194:42-52.
56. Watts DH, Brown ZA, Money D, et al. A double-blind, randomized, placebo-controlled trial of acyclovir in late pregnancy for the reduction of herpes simplex virus shedding and cesarean delivery. *Am J Obstet Gynecol* 2003;188:836–43.
57. Weinstock H, Berman S, Cates W Jr. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. *Perspect Sex Repro Health* 2004; 36(1):6-10.
58. Whittington WL, Celum CL, Cent A, Ashley RL. Use of a glycoprotein G-based type-specific assay to detect antibodies to herpes simplex virus type 2 among persons attending sexually transmitted disease clinics. *Sex Transmit Dis* 2001;28:99–104.
59. Xu F, Sternberg MR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. *JAMA* 2006; 296:964-73.
60. Zimet GD, Rosenthal SL, Fortenberry JD, et al. Factors predicting the acceptance of herpes simplex virus type 2 antibody testing among adolescents and young adults. *Sex Transmit Dis* 2004; 31:665–9.
61. Zuckerman RA et al. Herpes simplex virus (HSV) suppression with valaciclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomised, double blind, placebo-controlled crossover trial. *J Infect Dis* 2007; 196: 1500 – 1508.

Websites and Other Resources

1. CDC, Division of STD Prevention: www.cdc.gov/std
2. National Network of STD/HIV Prevention Training Centers:
<http://depts.washington.edu/nnptc/>
3. 2006 CDC STD Treatment Guidelines: <http://www.cdc.gov/STD/treatment/>
4. CDC-INFO
1-800-CDC-INFO (800-232-4636)
TTY: 1-888-232-6348
In English, en Español
5. CDC National Prevention Information Network (NPIN): www.cdcpin.org
6. American Social Health Association (ASHA): www.ashastd.org
7. International Herpes Management Forum (IHMF): <http://www.ihmf.org/>